Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2774 - Clinical efficacy observation for Endostar combined with chemotherapy treating gastric cancer peritoneal carcinomatosis

Date

09 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Gastric Cancer

Presenters

Hong Ma

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

H. Ma, A. Huang, J. Yao, T. Zhang

Author affiliations

  • Cancer Center, Wuhan Union Hospital (of Tongji Medical College of HUST), 430022 - wuhan/CN
More

Resources

Abstract 2774

Background

The peritoneal carcinomatosis of gastric cancer is a current therapeutic difficulty and the related clinical data are still limited so far. In this study, we evaluated efficacy and safety of the recombinant human endostatin (Endostar) characterized by broad-spectrum anti-angiogenesis combined with chemotherapy on gastric cancer peritoneal carcinomatosis.

Methods

From Jan. 2014 to Dec. 2016, 33 advanced stage gastric cancer patients associated with peritoneal carcinomatosis were enrolled. Their pathological information, imaging as well as therapy information were retrospectively analyzed. Twenty-one patients only received systemic chemotherapy as control group, and twelve patients received Endostar combined with chemotherapy as combination therapy group. All the 33 patients were evaluated on phase-efficacy and followed-up to record survival time. The tumor time to progression (TTP), overall survival (OS), Objective Response Rate (ORR), disease control rate (DCR) and therapy-related adverse reactions were evaluated to confirm effect of Endostar therapy.

Results

All the patients were evaluable. The evaluation on efficacy indicated that Endostar combined with chemotherapy increased ORR (41.6% vs. 23.81%) and DCR (83.3% vs. 61.91%) compared with control group, although there was no statistical difference between them. The survival analysis indicated that Endostar combined with chemotherapy effectively extended time to disease progression (4.60 ± 0.32 months vs. 3.50 ± 0.34 months, P = 0.03), and the median OS (15.80 ± 3.4 months vs. 9.80 ± 0.7 months, P = 0.01) compared with single chemotherapy. Furthermore, the evaluation on adverse reactions indicated that combination therapy did not have more adverse reactions.

Conclusions

The recombinant endostatin with broad-spectrum anti-angiogenesis could effectively control the development of peritoneal carcinomatosis disease and extend survival with high safety and tolerance. However, further prospective study needs to be performed to confirm the clinical application value.

Clinical trial identification

This retrospective study was approved by hospital ethical committee and all informed consent were obtained.

Legal entity responsible for the study

This study was approved by hospital ethical committee and all informed consent were obtained.

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.